Cortalix is a biotechnology company specializing in the development of nutraceuticals, diagnostics, radiopharmaceuticals, and immunotherapeutics. Our proprietary single-domain antibody (sdAb) discovery platform, also known as a nanobody platform, utilizes synthetic sdAb libraries to target novel biomarkers.
Our focusCortalix operates through three main pillars:
Internal Programs: We are advancing clinical candidates targeting PDGFRA, PDGFRB, FAP, IGF2R, and EGFR for applications in ImmunoPET imaging, targeted ImmunoRT, and immunotherapy, particularly in fibrosis and fibrotic cancers. These programs are available for licensing.
Partner Programs: We collaborate with companies and academic research groups to screen and select suitable sdAb candidates for novel targets using our synthetic sdAb discovery platform. We assist in developing these sdAbs into fully-fledged applications and facilitate connections with downstream partners for production.
Services: We offer stand-alone sdAb selection and development projects on a fee-for-service basis for CROs, biotech and pharma companies, and research groups. Applications include targeted therapy, immunotherapy, research tools, and bioanalytical applications such as immunohistochemistry, fluorescence imaging, tailored affinity columns, and ELISA development and validation.
At Cortalix, our mission is to leverage modern, affordable, and animal-free nanobody library technology to develop next-generation diagnostics, therapeutics, and bio-analytical tools. Headquartered in Groningen, Netherlands, we are committed to supporting scientific innovation through our expertise in single-domain antibodies.
Website: www.cortalix.com
